N/A N=4 Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova
Ulcerative Colitis
Primary: Change From Baseline of Mucus Production at 12 Weeks and 24 Weeks as Assessed by Histopathology
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=176 Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients
Trichuris Infection · Helminthiasis
Primary: Cure Rate — 1; 31; 6; 40 Participants
Phase 2 N=250 Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Crohn's Disease
Primary: Evaluate the Effects of TSO on the Induction of Response in Crohn's Disease, as Measured Primarily by Crohn's Disease Activity Index (CDAI) — 55; 58 Participants
Phase 1 N=36 Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Crohn's Disease
Primary: Incidence of Adverse Events — 7; 4; 1; 7 events
Phase 3 N=1,673 Efficacy and Safety of IVM/ALB Co-administration
Trichuriasis
Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants
Phase 2 N=700 Albendazole Dose Finding and Pharmacokinetics in Children and Adults
Trichuriasis · Hookworm Infections
Primary: Cure Rate Against T. Trichiura and Hookworm Infections — 4; 2; 4; 5 Participants
Phase 3 N=255 Efficacy and Safety of MOX/ALB Co-administration
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) of Moxidectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura — 15.3; 13.4 percentage of participants (%)
Phase 3 N=536 Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Egg Reduction Rate Against T. Trichiura — 96.8; 99.0; 86.2; 94.2 Percent change
Phase 3 N=224 Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 69.4; 16.2; 11.8 percentage of participants cured (%)
N/A N=3,345 Modified Instrumentation for Surgery to Correct Trichiasis
Trachoma
Primary: Number of Eyelids With Presence of Recurrent Trichiasis — 948; 1062; 721; 612 eyelids
Phase 3 N=623 Trichomonas Vaginalis Repeat Infections Among HIV Negative Women
Vaginitis Trichomonal or Due to Trichomonas
Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants
Phase 4 N=128 Partnership for Rapid Elimination of Trachoma
Trachoma
Primary: Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection at Baseline — 30.7; 30.3; 31.1; 30.5 community
N/A N=87 Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
Hookworm Infection
Primary: Size of Wheal Diameter at Site of Skin Test Application, Measured 15 Minutes After Injection — 3.5 cm
Phase 4 N=1,452 Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia
Trichiasis
Primary: Recurrent Trichiasis in Tetracycline and Azithromycin Groups — 45; 62 Participants — p=.047
Phase 2 N=260 Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 17.5; 50.0; 83.3; 84.6 percentage of participants cured (%)
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Phase 2 N=12 Desensitising Celiac Disease Patients With the Human Hookworm
Celiac Disease
Primary: Duodenal Villus Height:Crypt Depth — 2.73; 2.73 Ratio — p=0.693
Phase 3 N=356,912 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Helminthiasis · Filariasis
Primary: Comparison of Arms - Benin — 322; 748; 11; 11 Participants
Phase 4 N=270 Trichomonas Vaginalis Recurrence Among HIV+ Women
Trichomonas Infections · HIV Infections
Primary: TV Culture Positive Result — 11; 21 participants — p=.045
Phase 2 N=40 Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis
Trichomonas Vaginitis
Primary: Percentage of Participants Cured of Vaginal Trichmonas — 90; 90; 88 percentage of participants
Phase 3 N=27 Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Clostridium Enterocolitis · Pseudomembranous Colitis
Primary: Nitazoxanide — 27 participants
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Phase 2 N=39 Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
Hookworm Infections
Primary: Detectable Hookworm Infection — 0; 0; 0; 0 Participants
Phase 2 N=354 Praziquantel in Children Under Age 4
Schistosomiasis · Schistosomiasis Mansoni · Schistosoma Japonicum Infection
Primary: Treatment Efficacy — 96; 98; 96; 98 percentage change
N/A N=421 Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections
Upper Respiratory Tract Infections
Primary: Number of Subjects With an Investigator Assessment of Clinical Outcome (Success/Failure) at End of Study — 275; 133 participants
Phase 2 N=40 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
Lymphatic Filariasis
Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2
Phase 3 N=214 Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections
Necator Americanus Infection
Primary: Cure Rate — 16.3; 28.3; 18.8 percentage of participants